Senses Disorder TRIZ Cases

Suspendable microcarrier matrices enable scalable retinal pigment epithelium cell expansion, reducing contamination risks and lot variability.

Sub-inhibitory glycerol monolaurate targets enzymatic degradation to resolve antibiotic resistance trade-offs in dry eye therapy.

Topical keratolytic conjugates dissolve hyperkeratinized obstructions in meibomian glands to restore normal glandular function.

Tri-specific binding molecules inhibit synergistic pro-inflammatory activity while maintaining formulation stability.

A portable photodynamic therapy device uses a curved cupula to focus light from multiple sources onto a single focal point.

Engineered zinc finger proteins upregulate NT-3 and GDNF expression via specific DNA binding.

Benzisoxazole compounds stimulate neural stem cell proliferation to support brain regeneration.

Sequential chelating resin treatment and pH adjustment reduce iron ion concentrations in UP4U solutions to 10 ppm or less for pharmaceutical-grade purity.

Modifying benzofuran structures reduces cytotoxicity while maintaining strong suppression of inflammatory mediators like NO, IL-6, and TNF-alpha.

Modified peptide forms disulfide bonds to enhance stability, resolving the trade-off between cancer cell killing efficacy and normal cell toxicity.

Segmented purinyl derivatives selectively target SK channels to resolve the trade-off between limited availability and precise therapeutic effectiveness.

Hydrophilic substituents modify ester prodrug polarity to resolve hydrophobicity barriers, enabling corneal penetration and aqueous diffusion.

Segmenting alpha adrenergic receptors into selective compounds reduces plasma catecholamine concentration and side effects.

Inhaled aclidinium delivers sustained bronchodilation while rapid plasma hydrolysis prevents systemic anticholinergic side effects.

Optimized BMP4 timing in suspension culture reduces recombinant protein costs while maintaining neural tissue integrity.

Histatin peptides reduce cholesterol accumulation and enhance cell viability by targeting TMEM97 and NPC1 pathways in lysosomal storage disorders.

Selective sGC activators restore cGMP production in oxidized enzymes to lower intraocular pressure, addressing treatment resistance in normotensive glaucoma.

A 2-heteroaryl-substituted indole derivative activates glucokinase to enhance insulin secretion and glucose uptake.

Administering a CYR61 activating agent to immune cells upregulates anti-angiogenic gene expression.

Selective sGC activators lower intraocular pressure in normotensive glaucoma patients by activating oxidized enzyme forms, reducing side effects.

Adding a chelating agent prevents insoluble precipitates in diquafosol eye drops, maintaining filtration efficiency and reducing eye irritation during storage.

NBL1 reduces myofibroblast growth to restore corneal transparency while facilitating rapid epithelial closure.

Novel kinase inhibitor compounds modulate tyrosine kinase signaling cascades to treat cell proliferative disorders.

Pyrazoline compounds act as mineralocorticoid receptor antagonists.

WBC targeting peptides transport cargo molecules into white blood cells via receptor-mediated endocytosis.

Sildenafil treats mitochondrial Complex V deficiency by reducing membrane potential to reverse symptoms.

Saposin A peptide fragments stimulate thrombospondin-1 expression, reducing toxicity while inhibiting metastasis.

Selective FP receptor agonism reduces intraocular pressure while avoiding ocular side effects like hyperemia.

Aromatic amido derivatives inhibit lysophosphatidic acid receptor 2, reducing adverse events through lower therapeutic dosages.

Targeting programmed necrosis alongside apoptosis prevents vision loss in AMD and RP.

A Crovalimab dosing regimen uses intravenous loading followed by subcutaneous maintenance doses.

Cyclic peptides with non-peptide bonds block CD44v6 signaling, resolving proteolytic degradation limits to regress metastases.

Controlled solvent cooling yields a stable A-type yonkenafil hydrochloride polymorph, resolving batch variability in clinical efficacy.

Mesenchymal stem cell conditioned medium preserves hexagonal cell shape and promotes high density, addressing donor shortages for transplantation.

Humanized anti-Factor D antibodies bind Factor D to inhibit biological activity, resolving uncontrolled inflammation in autoimmune diseases.

Replacing chlorine with a methyl group reduces cytotoxicity while Ficoll raises density to improve membrane visibility.

Replacing sodium chloride with polyols or amino acids alongside non-ionic surfactants reduces aggregation in high-concentration aflibercept formulations.

Targeting LC3B with aminomethylenecyclohexane-1,3-dione avoids side effects from non-specific antilysosomal agents.

Multilayer microparticles use polymer barriers to reduce initial burst release and sustain drug delivery.

Modified triazolopyridazine structures enhance membrane penetration and bioavailability for effective PAR1 inhibition.

Freeze-dried secretome extracts bioactive molecules from live cells, eliminating storage instability and immune rejection while preserving regenerative potency.

Ultrasound creates cavitation in the sclera to permeate macromolecules into the intrascleral space, bypassing invasive injections.